# US 2006/0142194 A1 · Methods and compounds for treating brain amyloidosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0142194 A1
- Document ID: US20060142194A1
- Status: Published application
- Kind: A1
- Application number: 11/274,493
- Filed: 2005-11-16
- Published: 2006-06-29
- Earliest claimed: 2000-09-19
- Assignees: Evotec NeuroSciences GmbH; UniversitäT ZüRich
- Inventors: Roger Nitsch; Johannes Pohlner; Axel Wollmer; Hasan Mohajeri
- Web page: https://patentgrep.com/patent/US20060142194A1

## CPC

- A61K 38/1709: {from mammals}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention discloses the use of (i) a fragment of the amyloid precursor protein (APP); or, (ii) a derivative of (i); or, (iii) a functional mimetic of (i) or (ii), in the preparation of a medicament for modulating CNS levels and/or activity of a member of the neprilysin family.

## Claims

### Claim at position 1

1-38. (canceled)

### Claim 39

A method of treating a neurodegenerative disorder, wherein the neurodegenerative disorder is brain amyloidosis or Alzheimer's disease, comprising increasing neutral endopeptidase-24.11 activity in a patient by administering to the patient a medicament containing
i) a fragment of the amyloid precursor protein,
ii) a derivative of the amyloid precursor protein obtained by varying the amino acid sequence of the fragment, or
iii) a functional mimetic of the fragment or the derivative.

### Claim 40 (depends on 39)

The method of claim 39 wherein the neurodegenerative disorder is brain amyloidosis.

### Claim 41 (depends on 39)

The method of claim 39 wherein the neurodegenerative disorder is Alzheimer's disease.

### Claim 42 (depends on 39)

The method of claim 39 wherein CNS levels of neutral endopeptidase-24.11 are increased.

### Claim 43 (depends on 39)

The method of claim 39 wherein neuronal or glial levels of neutral endopeptidase-24.11 are increased.

### Claim 44 (depends on 39)

The method of claim 39 wherein the fragment comprises an amino acid sequence of an extracellular and a membrane-spanning region of the amyloid precursor protein.

### Claim 45 (depends on 39)

The method of claim 39 wherein the fragment comprises a peptide of 38 to 43 amino acid length obtainable by proteolytic cleavage of the amyloid precursor protein using β- and/or γ-secretase.

### Claim 46 (depends on 39)

The method of claim 39 wherein the fragment comprises the Aβ1-42 peptide.

### Claim 47 (depends on 39)

The method of claim 39 wherein the fragment comprises the Aβ1-40 peptide.

### Claim 48 (depends on 39)

The method of claim 39 wherein the medicament contains the fragment, derivative, or functional mimetic in the form of a monomer or multimer.

### Claim 49 (depends on 39)

The method of claim 39 wherein the medicament contains the fragment, derivative, or functional mimetic in aggregated form.

### Claim 50 (depends on 39)

The method of claim 39 wherein the medicament contains the fragment, derivative, or functional mimetic in aggregated form as fibrils.

### Claim 51 (depends on 39)

The method of claim 39 wherein the fragment, derivative, or functional mimetic is synthetic.
